Talazoparib (TALZENNA) + enzalutamide (XTANDI) + ADT vs placebo + enzalutamide + ADT in first-line metastatic castration-sensitive prostate cancer with HRR gene alterations — Pfizer / Astellas
Explore Trial DataTALAPRO-3 builds on the topline results Pfizer announced in March 2026. Today's late-breaking oral presentation at ASCO 2026 (Abstract LBA5007, presented by Neeraj Agarwal, MD FASCO, Huntsman Cancer Institute, University of Utah) delivered the detailed dataset — including subgroup analyses, safety, and patient-reported outcomes — with concurrent publication in the New England Journal of Medicine.
↗
↗
↗
↗
↗
↗
↗
↗
↗
↗
↗
↗
TALAPRO-3 (NCT04821622) is a Phase 3, randomised, double-blind, placebo-controlled trial of talazoparib + enzalutamide + ADT versus placebo + enzalutamide + ADT in patients with first-line metastatic castration-sensitive prostate cancer (mCSPC / mHSPC) harboring homologous recombination repair (HRR) gene alterations. The trial enrolled 599 patients globally and tested whether moving the PARP inhibitor + AR-pathway inhibitor combination — already approved in mCRPC via TALAPRO-2 — into an earlier line of therapy can extend radiographic progression-free survival in a biomarker-selected population.
The trial is being discussed by KOLs as the first prospective Phase 3 demonstration that an HRR-selected PARPi + ARPI intensification strategy improves rPFS in the castration-sensitive setting. The headline numbers are large — an rPFS hazard ratio of 0.48 and a 3-year rPFS of 76.6% vs 56% — but KOLs are also flagging the cost: a 19% talazoparib discontinuation rate, two treatment-related deaths in the talazoparib arm versus zero on placebo, and an overall survival curve that is trending in favor of the experimental arm but has not yet reached statistical significance (3-yr OS 77.8% vs 71.6%, HR 0.767, P=0.0905). The clinical debate now centers on patient selection within the HRR-altered subgroup — how much additional benefit is enough to justify the added toxicity, particularly outside of BRCA-altered disease.
Global PI Neeraj Agarwal (Huntsman Cancer Institute, University of Utah) presented at the ASCO 2026 Bladder/Genitourinary oral session (May 30 2026, Abstract LBA5007), with simultaneous publication in NEJM. The trial sits alongside earlier mCRPC programs — TALAPRO-2 (the registrational mCRPC study for the same combination), PROpel (olaparib + abiraterone), and MAGNITUDE (niraparib + abiraterone) — and now extends the PARPi + ARPI question into the upfront, hormone-sensitive setting.
Phase 3, multicenter, randomised, double-blind, placebo-controlled trial (NCT04821622). Patients with HRR-altered 1L mCSPC randomised 1:1 to talazoparib 0.5 mg/day (or 0.35 mg/day for renal impairment) + enzalutamide 160 mg/day + ADT versus placebo + enzalutamide 160 mg/day + ADT. Stratification by high-volume vs low-volume disease and BRCA vs non-BRCA HRR alteration.
N=599 patients with metastatic castration-sensitive prostate cancer and at least one HRR gene alteration per the HRR12 panel (ATM, ATR, BRCA1, BRCA2, CDK12, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, RAD51C). Eligibility required ≤3 months of ADT before randomisation and no brain metastases. Enrolment spanned US, Canada, Europe, South America, and Asia-Pacific sites.
TALZENNA (talazoparib) + XTANDI (enzalutamide) + ADT. Pfizer is the talazoparib sponsor; enzalutamide is co-developed by Pfizer and Astellas. The combination is already FDA-approved in mCRPC (via TALAPRO-2, 2023). TALAPRO-3 is the first prospective Phase 3 test of the same regimen earlier in the disease course.
Primary: radiographic progression-free survival (rPFS) by blinded independent central review. Key secondary: overall survival, time to PSA progression, time to cytotoxic chemotherapy, objective response rate, safety, and patient-reported outcomes (EORTC QLQ-C30).
Talazoparib + enzalutamide + ADT delivered an rPFS hazard ratio of 0.48 versus placebo + enzalutamide + ADT, with the median rPFS not reached at >3 years of follow-up. The 3-year rPFS was 76.6% (TALA + ENZA) vs 56% (placebo + ENZA), a ~20-point absolute improvement at the 3-year landmark. Benefit was reported as consistent across pre-specified subgroups, including both BRCA-altered and non-BRCA HRR populations.
At 3 years, 78.3% of TALA + ENZA patients were free of PSA progression versus 62.7% on placebo + ENZA, hazard ratio 0.513, P<0.0001. This is the cleanest secondary signal supporting the rPFS result and reinforces that the experimental combination is delaying biochemical progression as well as radiographic progression.
3-year OS was 77.8% on TALA + ENZA versus 71.6% on placebo + ENZA, hazard ratio 0.767 (95% CI 0.564–1.044), P=0.0905. The OS curve is trending in favor of the experimental arm but has not crossed the threshold for statistical significance at this readout, and OS data remain immature. Multiple KOLs flagged the immature OS as the key open question driving how widely the regimen will be adopted in mCSPC.
The TALAPRO-3 safety profile is the focal point of the KOL nuance. The most clinically significant toxicity is hematologic: Grade ≥3 anemia in 51% of talazoparib-arm patients, with 40% requiring transfusions. Permanent discontinuation of talazoparib occurred in 19% of patients; 5% discontinued specifically because of anemia. There were 2 treatment-related deaths in the talazoparib arm and 0 in the placebo arm. Patient-reported outcomes on the EORTC QLQ-C30 "generally did not show clinically meaningful differences between the two arms, except for appetite loss." This is the toxicity envelope that KOLs (Yüksel Ürün, Suyog Cancer, and others) are weighing against the rPFS benefit when discussing which HRR-altered patients should receive upfront PARP intensification — particularly outside of BRCA-altered disease, where the rPFS benefit is smaller (HR 0.57) and the hematologic cost is the same. Sources: Agarwal ASCO 2026 oral · OncoDaily TALAPRO-3 coverage · Fierce Pharma May 30 2026 · KOL slide OCR.
Endpoint values verbatim from Neeraj Agarwal's ASCO 2026 oral presentation (LBA5007, May 30 2026) as captured by attending KOLs (@shilpaonc, @DrChoueiri, @tompowles1, @DrYukselUrun) and reconciled with simultaneous NEJM publication and the Pfizer / Astellas joint press release. See OncoDaily TALAPRO-3 detail and Pfizer press release.
Pfizer's TALAPRO-3 vs J&J's AMPLITUDE (niraparib + abi / Akeega): the two head-to-head Phase 3 reads in HRR-altered 1L mCSPC tell very different stories outside of BRCA.
Fierce Pharma (May 30 2026): “Pfizer appears to have one-upped Johnson & Johnson again in their PARP inhibitor battle in prostate cancer… Talzenna and Xtandi showed a robust 43% radiographic PFS improvement in the non-BRCA-mutated group, compared with 63% among BRCA-mutated patients.”
Primary publications, sponsor & institutional press releases, and major oncology media coverage around the Agarwal/Huntsman ASCO 2026 late-breaking oral presentation.
“These data are unprecedented in their depth and have the potential to change clinical practice for first-line metastatic castration-sensitive prostate cancer with HRR alterations. TALAPRO-3 demonstrates that combining a PARP inhibitor with enzalutamide and ADT can meaningfully delay disease progression in this earlier-line setting.”Source: Pfizer / Astellas press release · May 30 2026 ↗
“Talazoparib + Enzalutamide superior to Enzalutamide in mCSPC with HRR alterations in TALAPRO-3. rPFS not reached. NEJM published today.”Source: @DrChoueiri on X · May 30 2026 ↗
All 40 curated TALAPRO-3 tweets from #ASCO26 and pre-conference commentary — sorted positive → neutral → cautious. Text is verbatim from each KOL (leading reply-to @mentions and trailing media URLs trimmed for readability). Distribution: 4 positive · 29 neutral · 7 cautious.
